Correlation between physical status of human papilloma virus and cervical carcinogenesis

Abstract

The prevalence of human papilloma virus (HPV)-16 in patients with cervical cancer, the physical status of HPV-16 in patients with cervical lesions, and the role of HPV-16 integration in cervical carcinogenesis were investigated. HPV genotyping was performed by using PCR approach with the primer GP5+/GP6+ and type-specific primer on biopsy specimens taken operatively from 198 women. Multiple PCR was done to detect physical status of HPV-16 in a series of cervical liquid-based cytology samples and biopsy specimens obtained from different cervical lesions with HPV-16 infection, including 112 specimens with cervical cancer, 151 specimens with CIN I, 246 specimens with CIN and 120 specimens with CINIII. The results showed that there were 112 cervical cancer samples (56.57% of total cervical cancer patients) with HPV-16 infection. The frequency of HPV-16 pure integration was 65.18% (73/112), 56.57% (47/120), 23.58% (58/246) and 7.95% (12/151) in cervical cancer, CINIII, CINII and CINI patients respectively. In situ hybridization was performed on some paraffin-embedded sections of CINII, CINIII and cervical cancer to verify the physical status of HPV-16 infection. Significant difference was observed between cervical cancer and CIN I, CINII, CINIII in the frequency of HPV-16 integration (P<0.01). It is suggested that HPV-16 is the most prevalent type and is associated with cervical cancer. In the case of HPV-16 infection there are close associations between the severity of cervical lesions and the frequency of HPV-16 integration. The application of testing HPV genotyping and physical status based on detection of HC-II HPV DNA would be in favor of predicting the prognosis of cervical precancerosis and enhancing the screening accuracy of cervical cancer.

Keywords

human papilloma virus / cervical cancer / genotyping / physical status / integration

References

[1] RaoY.M., WangH.Y., FanL.S., et al.. Effects of MTA1 gene transfection on adhesion, migration and invasiveness of Hela cells by altered expression of MMP29 and β-catenin. Acta Med Univ Sci Technol Huazhong (Chinese), 2011, 40(1): 32-36

[2] DongH., LiS., WangD., et al.. Comparison of the biological behaviors and prognostic factors in cervical adenocarcinoma and squamous carcinoma. Acta Med Univ Sci Technol Huazhong (Chinese), 2010, 39(2): 254-257

[3] MooreP.S., ChangY.. Why do viruses cause cancer? Highlights of the first century of human tumor virology. Nature, 2010, 10(12): 878-889

[4] MatovinaM., SabolI., GrubišićG., et al.. Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. Gynecol Oncol, 2009, 113: 120-127

[5] Narisawa-SaitoM., YoshimatsuY., OhnoS., et al.. An in vitro, multistep carcinogenesis model for human cervical cancer. Cancer Res, 2008, 68(14): 5699-5705

[6] AnderssonS., SafariH., MintsM., et al.. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer, 2005, 92: 2195-2200

[7] WentzensenN., VinokurovaS., KnebelV., et al.. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res, 2004, 64(11): 3878-3884

[8] PettM., ColemanN.. Integration of high-risk human papillomavirus: a key event in carcinogenesis?. J Pathol, 2007, 212(4): 356-367

[9] JacobsM.V., SnijdersP.J., WalboomersJ.M., et al.. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol, 1997, 35(3): 791-795

[10] KrausI., MoldenT., HolmR., et al.. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol, 2006, 44(4): 1310-1317

[11] KrausI., MoldenT., ErnoL.E., et al.. Human papillomavirus oncogenic expression in the dysplasticportic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer, 2004, 90(7): 1407-1413

[12] GrahamD.A., HerringtonC.S.. HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities. Mol Pathol, 2000, 53(4): 201-206

[13] WHO Library Cataloguing-in-Publication Data. World health statistics 2010,. ISBN 978924 5563983

[14] HuangB.Y., ZhouY.G., XuY.H., et al.. Study on the detecting genotypes of human papillomavirus infection by using flow-through hybridization and gene chip. Chin J Lab Diagn (Chinese), 2009, 13(8): 1065-1067

[15] VonettaM.W., MariaF., UbaldoS., et al.. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol, 2011, 6(1): 45-57

[16] DingW.C., TianY., WuP., et al.. Analysis on infection status of cervical human papillomavirus in 3753 women. Zhongguo Fuyou Baojian (Chinese), 2010, 24: 3390-3392

[17] NambaruL., MeenakumariB., SwaminthanR., et al.. Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pacific J Cancer Prev, 2009, 10: 355-360

[18] Arias-PulidoH., PeytonC.L., JosteN.E., et al.. Human papillomavirus type 16 integration in cervical carcinoma in situ, and in invasive cervical cancer. J Clin Microbiol, 2006, 44(5): 1755-1762

[19] GiulianoA.R.. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine, 2008, 26(S10): K17-K28

[20] MichaelJ.L., JamesR.A., JensP.K., et al.. Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers. J Virol, 2011, 85(4): 1645-1654

[21] ShuklaS., BhartiA.C., MahataS., et al.. Application of a multiplex PCR to cervical cells collected by a paper smear for the simultaneous detection of all mucosal human papillomaviruses (HPVs) and typing of high-risk HPV types 16 and 18. J Med Microbiol, 2010, 59(Pt11): 1303-1310

[22] YoshidaT., SanoT., OyamaT., et al.. Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. Virchows Arch, 2009, 455(3): 253-259

[23] CriccaM., VenturoliS., LeoE., et al.. Disruption of HPV-16 E1 and E2 genes in precancerous cervical lesions. J Virol Met, 2009, 158(1–2): 180-183

[24] SaunierM., Monnier-BenoitS., MaunyF., et al.. Analysis of human papillomavirus type 16 (HPV-16) DNA load and physical state for identification of HPV-16-infected women with high-grade lesions or cervical carcinoma. J Clin Microbiol, 2008, 46(11): 3678-3685

[25] SathishN., AbrahamP., SridharanG., et al.. E2 sequence variations of HPV-16 among patients with cervical neoplasia seen in the Indian subcontinent. Gynecol Oncol, 2004, 95(2): 363-369

[26] BouletG.A.V., BenoyI.H., DepuydtC.E., et al.. Human papillomavirus 16 load and E2/E6 ratio in HPV-16-positive women: biomarkers for cervical intraepithelial neoplasia ≥2 in a lLiquid-based cytology setting?. Cancer Epidemiol Biomarkers Prev, 2009, 18(11): 2992-2999